Do reductions in ghrelin contribute towards antipsychotic-induced weight gain?

Schizophrenia Research

Volumn 210, Issue , 2019, Pages 301-302

  Firth, Joseph ^a,b,c   Teasdale, Scott B ^d,e   Jackson, Sarah E ^f   Vancampfort, Davy ^g   Siskind, Dan ^h,i   Sarris, Jerome ^a,j   Solmi, M ^k,l  

^a WESTERN SYDNEY UNIVERSITY   (Australia)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF LEUVEN   (Belgium)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ Mobile Intensive Rehabilitation Team   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k UNIVERSITY OF PADOVA   (Italy)

^l UNIVERSITY HOSPITAL OF PADOVA   (Italy)

more..

Author keywords

Antipsychotic; Cardiovascular; Metabolic; Nutrition; Obesity; Psychosis

Indexed keywords

GHRELIN; NEUROLEPTIC AGENT; OLANZAPINE;

BODY MASS; BODY WEIGHT GAIN; DRUG EFFECT; DRUG SAFETY; HORMONE ACTION; HUMAN; LETTER; LIFESTYLE; MEDICAL RESEARCH; METABOLISM; OBESITY; PRIORITY JOURNAL; SIDE EFFECT; ADULT; META ANALYSIS (TOPIC); PSYCHOSIS;

ADULT; ANTIPSYCHOTIC AGENTS; GHRELIN; HUMANS; META-ANALYSIS AS TOPIC; OLANZAPINE; PSYCHOTIC DISORDERS; WEIGHT GAIN;

EID: 85068221364     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2018.12.043     Document Type: Letter

References (10)

1. Basoglu, C., Oner, O., Gunes, C., Semiz, U.B., Ates, A.M., Algul, A., et al. Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis. Int. Clin. Psychopharmacol. 25 (2010), 165–171.
2. Firth, J., Stubbs, B., Teasdale, S.B., Ward, P.B., Veronese, N., Shivappa, N., et al. Diet as a hot topic in psychiatry: a population-scale study of nutritional intake and inflammatory potential in severe mental illness. World Psychiatry 17 (2018), 365–367.
3. Firth, J., Stubbs, B., Vancampfort, D., Schuch, F.B., Rosenbaum, S., Ward, P.B., et al. The validity and value of self-reported physical activity and accelerometry in people with schizophrenia: a population-scale study of the UK biobank. Schizophr. Bull. 44 (2018), 1293–1300.
4. Geliebter, A., Gluck, M.E., Hashim, S.A., Plasma ghrelin concentrations are lower in binge-eating disorder. J. Nutr. 135 (2005), 1326–1330.
5. Goetz, R.L., Miller, B.J., Meta-analysis of ghrelin alterations in schizophrenia: effects of olanzapine. Schizophr. Res. 206 (2019), 21–26.
6. Higgins, S.C., Gueorguiev, M., Korbonits, M., Ghrelin, the peripheral hunger hormone. Ann. Med. 39 (2007), 116–136.
7. Kim, B.-J., Sohn, J.-W., Park, C.-S., Hahn, G.-H., Koo, J., Noh, Y.-D., et al. Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine. J. Korean Med. Sci. 23 (2008), 685–690.
8. Mayfield, K., Siskind, D., Winckel, K., Russell, A.W., Kisely, S., Smith, G., et al. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. J. Psychopharmacol. (Oxf.) 30 (2016), 227–236.
9. Smith, R.C., Rachakonda, S., Dwivedi, S., Davis, J.M., Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients. Psychiatry Res. 199 (2012), 159–163.
10. Tschöp, M., Weyer, C., Tataranni, P.A., Devanarayan, V., Ravussin, E., Heiman, M.L., Circulating ghrelin levels are decreased in human obesity. Diabetes 50 (2001), 707–709.